Bigfoot Biomedical, Inc., a diabetes company using artificial intelligence to develop solutions for optimizing the dosing and delivery of insulin, announces a new agreement with Eli Lilly and Company.
The partnership will allow the integration of Lilly’s insulin products into Bigfoot’s systems currently in development.
“Our agreement with Lilly will enable us to bring Bigfoot’s insulin delivery innovations to the millions of people who trust and rely on Lilly’s insulin products,” said Jeffrey Brewer, Bigfoot Biomedical co-founder, and CEO in a statement. “We are thrilled to partner with Lilly in our efforts to innovate for people with diabetes and their care teams.”
Bigfoot is reimagining insulin therapy for the healthcare system of tomorrow.
The company is bringing to market a first-of-its-kind comprehensive digital drug delivery platform addressing all segments of the insulin-requiring population of people with diabetes.
“By employing data-driven intelligence across an integrated device ecosystem of medical devices, we are transforming diabetes care with a fully comprehensive digital drug delivery platform delivered and experienced as a service,” explains Melissa Lee, Bigfoot Biomedical’s media contact.
Lee says Bigfoot Biomedical is founded by people with a personal connection to type 1 diabetes. She says the company has approximately 400 years of living with T1D across their team.
Bigfoot’s vision is to deliver injection systems as a monthly subscription and bring together insulin dosing support and glucose management with the goal of reducing the daily burden of diabetes management for people with insulin-requiring diabetes.
The company also intends to provide straightforward methods for healthcare providers to review comprehensive data by virtue of a connected service, with the goal of enabling care teams to provide more informed dosing regimens.
Two Products: Bigfoot Loop and Bigfoot Inject
The company is developing a closed loop automated insulin delivery system for which they have completed initial clinical trials.
The system, which is called the “Bigfoot Loop” is a Bluetooth-enabled insulin pump that will connect to the next generation of Abbott’s FreeStyle® Libre CGM and a smartphone mobile app.
The start-up is preparing now for a pivotal trial in the U.S., anticipated to begin later this year.
Also under development is “Bigfoot Inject,” a Bluetooth-connected insulin pen solution for injection users that will use the same sensor and a mobile app to track and titrate basal and mealtime insulin doses.
The company anticipates commercial launch of its first two systems, Bigfoot Inject and Bigfoot Loop, in 2020, pending completion of a pivotal clinical trial and subsequent regulatory approvals.
Image Above: Bigfoot Loop Device ecosystem, courtesy of Bigfoot Biomedical.
Bigfoot Biomedical Announces Next Step for Connected Insulin Injection System. (2018, Jan. 7). BusinessWire. Retrieved: https://www.businesswire.com/news/home/20190107005321/en